Gates MRI- COD-01-T01-01 Amendment 1

Name of study: 
Gates MRI- COD-01-T01-01 Amendment 1

Targeted disease: 
COVID-19

Purpose of study:
A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban(Xarelto®) for high risk people with mild COVID-19.

Is this a pre- or post- market study?: 
Pre-Market Study (151445)

Is the study of a controlled or observational design? 
Controlled

What is the funding source?: 
Sponsor funded- Bill & Melinda Gates Medical Research Institute

Where is the study being conducted?
Multi-Center Trial

Lead Institution:
Allergy & Asthma Medical Group and Research Center A P.C

City and State: 
San Diego, California

When the study is being conducted: 
Start Date: 9/1/2020
End date: Unknown

What website should a person use to register for the study?
www.allergyandasthma.com

Who should a person contact to register for the study?
Name: Silvia Cedillo
Phone: 858.268.2368 ext 130
Email:     [email protected]

Who is sponsoring this study?
Bill & Melinda Gates Medical Research Institute (Gates MRI)

What is the identifier for this study on ClinicalTrials.gov?
NCT04504032

Page last updated: February 23, 2021

Freedom From Smoking | Virtual Training
, | Aug 04, 2021
Freedom From Smoking Facilitator Training
, | Aug 11, 2021